- NeoTherapeutics has reported interim results from its single-dose,dose-ranging Phase I/II trial of AIT-082, and concludes that the drug is orally available, has no serious side effects and improved memory function in 10 patients with Alzheimer's disease. AIT-082 is reported to increase levels of neurotrophic factors in damaged or degenerating neurons.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze